Education
About Us
Working with TipRanks
Follow Us
CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Top Page
CV Sciences
(OTC:CVSI)
42Neutral
CV Sciences (CVSI) vs. S&P 500 (SPY)
Market Cap
$4.98M
Dividend YieldN/A
Average Volume (3M)151.71K
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth-1.87%
EPS Growth-165.87%
CountryUS
Employees47
SectorHealthcare
Sector Strength56
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding184,263,660
10 Day Avg. Volume73,467
30 Day Avg. Volume151,710
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.92
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CV Sciences Business Overview & Revenue Model
Company DescriptionCV Sciences, Inc. (CVSI) is a prominent company in the life sciences sector, primarily focused on developing, manufacturing, and selling plant-based cannabidiol (CBD) products. The company's offerings include consumer health products that promote health and wellness. These products are sold under the PlusCBD™ brand, which is recognized for its quality and safety standards. CV Sciences operates in the nutraceutical industry, leveraging innovative research to deliver effective CBD-based solutions.
How the Company Makes MoneyCV Sciences generates revenue through the sale of its CBD-based products, mainly under the PlusCBD™ brand. The company sells these products through various distribution channels, including direct-to-consumer sales via their website, retail partnerships, wholesalers, and other e-commerce platforms. Key revenue streams include a range of CBD formulations such as oils, capsules, gummies, and topicals, which cater to diverse consumer needs for wellness and health. The company may also engage in strategic partnerships and collaborations that enhance its market presence and distribution capabilities, contributing to its earnings.
CV Sciences Financial Statement Overview
Summary
CV Sciences faces significant financial challenges, characterized by declining revenues, persistent losses, and weak cash flow. While the company's low debt levels suggest limited financial leverage risk, the negative profitability metrics and cash burn rate pose serious concerns for sustainable operations.Income Statement
CV Sciences is struggling with declining revenue and profitability. The TTM revenue has decreased by 2.38% compared to the previous year, and the company is operating at a net loss. The gross profit margin for TTM is 46.29%, which shows some efficiency in production, but the net profit margin is negative, indicating overall unprofitability. Additionally, both EBIT and EBITDA margins are negative, reflecting operational challenges.30
Negative
Balance Sheet
The balance sheet shows moderate financial health with a debt-to-equity ratio of 0.04 for the TTM, indicating low leverage. However, the equity ratio is 26.11%, which suggests the company is not heavily reliant on equity financing. The return on equity is negative due to net losses, highlighting profitability issues.45
Neutral
Cash Flow
The cash flow statement indicates negative free cash flow and operating cash flow in the TTM, signaling potential liquidity issues. The operating cash flow to net income ratio is 0.32, and the free cash flow to net income ratio is negative, both underscoring cash generation challenges.35
Negative
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 16.00M | 16.20M | 20.05M | 24.43M | 53.70M | Gross Profit |
| 7.08M | 5.55M | 8.62M | 11.01M | 35.09M | EBIT |
| 3.36M | -6.85M | -18.45M | -22.59M | -17.24M | EBITDA |
| 3.85M | -5.66M | -14.00M | -21.72M | -15.69M | Net Income Common Stockholders |
| 3.10M | -8.21M | -15.55M | -22.28M | -16.61M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.32M | 611.00K | 1.38M | 4.02M | 9.11M | Total Assets |
| 9.20M | 12.74M | 18.07M | 30.63M | 52.69M | Total Debt |
| 442.00K | 1.53M | 922.00K | 7.77M | 10.24M | Net Debt |
| -875.00K | 917.00K | -453.00K | 3.75M | 1.13M | Total Liabilities |
| 6.30M | 13.51M | 14.52M | 19.41M | 23.54M | Stockholders Equity |
| 2.90M | -777.00K | 3.54M | 11.21M | 29.15M |
| Cash Flow | Free Cash Flow | |||
| 2.25M | -1.89M | -7.52M | -8.36M | -3.37M | Operating Cash Flow |
| 2.25M | -1.89M | -7.49M | -7.30M | -2.14M | Investing Cash Flow |
| -156.00K | 0.00 | -35.00K | -1.06M | -1.24M | Financing Cash Flow |
| -1.39M | 1.12M | 4.37M | 3.27M | 47.00K |
CV Sciences Technical Analysis
Negative
0.03
Price Trends
0.03
Negative
0.03
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
45.27
Neutral
76.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSI, the sentiment is Negative. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.27 is Neutral, neither overbought nor oversold. The STOCH value of 76.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVSI.
CV Sciences Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.35B | 3.81 | -42.57% | 2.86% | 17.10% | 1.33% | |
47 Neutral | $8.08M | ― | -18.06% | ― | -30.19% | 75.92% | |
42 Neutral | $4.98M | ― | -101.92% | ― | -1.87% | -165.87% | |
42 Neutral | $12.24M | ― | -291.50% | ― | -22.58% | 82.94% | |
37 Underperform | $1.18M | ― | -60.98% | ― | -18.02% | 78.28% |
* Healthcare Sector Average
Performance Comparison
CVSI
CV Sciences
0.03
-0.02
-40.00%
AYTU
Aytu BioScience
1.31
-1.75
-57.19%
YCBD
cbdMD
0.19
-0.66
-77.65%
FLGC
Flora Growth
0.63
-0.95
-60.13%
CV Sciences Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: 0.00%|
Next Earnings Date:May 19, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant efforts in cost reduction and product innovation, with strategic acquisitions contributing to future growth potential. However, the company faces revenue pressure, liquidity challenges, and regulatory uncertainties. Despite these challenges, the company's actions suggest a focus on sustainable growth and efficiency.Q4-2024 Updates
Positive Updates
Gross Margin Improvement
Gross margin improved to 45.6% in fiscal year 2024, up from 44.3% in 2023, indicating better cost efficiency and product mix.
Successful Product Innovation
Launch of new product lines such as PlusHealth supplements and Plus CBD pet chews, contributing to 28% of the full-year 2024 revenue.
Strategic Acquisitions
Completed two acquisitions, Cultured Foods and Elevated Soft Gels, to expand product lines and increase manufacturing capabilities.
Revenue Stability in Competitive Market
Maintained revenue of $15.7 million in 2024 despite a challenging market, showing resilience compared to competitors facing declines.
Cost Reduction Efforts
Reduced operating expenses by 5.4% in 2024, with ongoing efforts to enhance cost efficiency.
Negative Updates
Slight Year-over-Year Revenue Decline
Revenue decreased from $16 million in 2023 to $15.7 million in 2024, reflecting difficulties in the market environment.
Cash Position Decrease
Cash decreased from $1.3 million at the end of 2023 to $0.5 million at the end of 2024, highlighting liquidity challenges.
Operating Loss
Reported an operating loss of $0.6 million in Q4 2024, though an improvement from the previous year's loss of $0.9 million.
Regulatory Challenges
Continued regulatory challenges in the hemp and cannabis industries, creating uncertainty and potential compliance costs.
Company Guidance
During the CV Sciences conference call, management provided guidance for fiscal year 2024, highlighting several key financial metrics and strategic initiatives. The company reported a slight decrease in revenue to $15.7 million from $16 million in 2023, amidst challenging market conditions. However, they achieved an improved gross margin of 45.6%, up from 44.3% the previous year, and reduced operating expenses by 5.4% to $9.4 million. The company emphasized its focus on product innovation, cost efficiency, and strategic acquisitions to drive profitable growth. Notable product launches included the PlusHealth line of cannabinoid-free supplements and the expansion of their Plus CBD pet line. Additionally, CV Sciences undertook two acquisitions—Cultured Foods and Elevated Soft Gels—to enhance their product offerings and achieve greater cost efficiency. The company also entered a strategic relationship with Chewy to bolster their pet product distribution. Despite a GAAP net loss of $0.7 million in Q4 2024, they maintained a stable revenue run rate and improved cash management, reducing operating cash usage significantly from $1.9 million in 2023 to $0.9 million in 2024. The company is optimistic about generating positive cash flow in the second half of 2025, driven by operational synergies from recent acquisitions.CV Sciences Corporate Events
Product-Related AnnouncementsM&A TransactionsBusiness Operations and StrategyFinancial Disclosures
CV Sciences Reports 2024 Financial Results and Growth Plans
Neutral
Mar 27, 2025
CV Sciences reported its financial results for the fiscal year ending December 31, 2024, with revenues of $15.7 million, a slight decline from the previous year. The company achieved a gross margin improvement to 45.6% and reduced operating expenses by 5.4%. Despite an operating loss of $2.2 million, the adjusted EBITDA loss improved significantly. The company expanded its product offerings with new launches and strategic partnerships, including the acquisition of Elevated Softgels and the launch of the Lunar Fox plant-based product line. CV Sciences aims to continue its growth trajectory through innovation and strategic mergers and acquisitions.
M&A TransactionsLegal Proceedings
CV Sciences Disputes Stock Purchase Agreement Termination
Negative
Feb 11, 2025
On November 21, 2024, CV Sciences, Inc. announced a Stock Purchase Agreement to acquire all shares of Extract Labs, a Colorado corporation, along with shares from Higher Love Wellness Company and Craig Henderson. However, on February 5, 2025, the sellers indicated they could not proceed due to a lack of bank consent, leading to a purported termination of the agreement. CV Sciences disputes this termination and is exploring its options.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.